TearLab (OTCMKTS: TEAR) and Cooper Companies (NYSE:COO) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, earnings, risk, valuation and dividends.

Profitability

This table compares TearLab and Cooper Companies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
TearLab -60.22% N/A -75.54%
Cooper Companies 16.45% 16.00% 9.90%

Risk & Volatility

TearLab has a beta of 2.92, indicating that its stock price is 192% more volatile than the S&P 500. Comparatively, Cooper Companies has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for TearLab and Cooper Companies, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TearLab 0 0 4 0 3.00
Cooper Companies 0 5 7 0 2.58

TearLab presently has a consensus target price of $5.75, suggesting a potential upside of 812.70%. Cooper Companies has a consensus target price of $260.63, suggesting a potential upside of 9.46%. Given TearLab’s stronger consensus rating and higher probable upside, analysts plainly believe TearLab is more favorable than Cooper Companies.

Dividends

Cooper Companies pays an annual dividend of $0.06 per share and has a dividend yield of 0.0%. TearLab does not pay a dividend. Cooper Companies pays out 0.9% of its earnings in the form of a dividend.

Institutional and Insider Ownership

12.2% of TearLab shares are held by institutional investors. Comparatively, 96.8% of Cooper Companies shares are held by institutional investors. 12.0% of TearLab shares are held by company insiders. Comparatively, 1.6% of Cooper Companies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares TearLab and Cooper Companies’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
TearLab $28.01 million 0.13 -$19.92 million ($3.10) -0.20
Cooper Companies $1.97 billion 5.93 $273.91 million $6.97 34.16

Cooper Companies has higher revenue and earnings than TearLab. TearLab is trading at a lower price-to-earnings ratio than Cooper Companies, indicating that it is currently the more affordable of the two stocks.

Summary

Cooper Companies beats TearLab on 10 of the 15 factors compared between the two stocks.

TearLab Company Profile

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc., develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care. Its product, the TearLab Osmolarity System, enables the measurement of tear osmolarity in the doctor’s office. The TearLab Osmolarity System consists of approximately three components: the TearLab disposable, the TearLab Pen, and the TearLab Reader. The TearLab disposable is a single-use microfluidic microchip. The TearLab Pen is a hand-held device that interfaces with the TearLab disposable. The TearLab Reader is a small desktop unit that allows for the docking of the TearLab Pen.

Cooper Companies Company Profile

The Cooper Companies, Inc. is a global medical device company. The Company operates through two business units: CooperVision, Inc. and CooperSurgical, Inc. CooperVision offers soft contact lenses for the vision correction market. CooperVision develops, manufactures and markets a range of single-use, two-week and monthly contact lenses. CooperVision services three primary regions: the Americas; Europe, the Middle East and Africa (EMEA), and Asia Pacific. CooperVision offers spherical, aspherical, toric, multifocal and toric multifocal lens products in various modalities. CooperVision’s products are primarily manufactured at its facilities located in the United Kingdom, Puerto Rico, Hungary, Costa Rica and New York. CooperSurgical offers an array of products and services focused on advancing the health of families through a portfolio of products and services focusing on women’s health, fertility and diagnostics.

Receive News & Stock Ratings for TearLab Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TearLab Corporation and related stocks with our FREE daily email newsletter.